国产敷贴器治疗孤立性脉络膜血管瘤的临床效果

doi:10.3760/cma.j.issn.1674-845X.2019.08.003

摘要
图/表
参考文献(19)
相关文章 (1)

全文: PDF 294KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

目的：评价国产敷贴器治疗孤立性脉络膜血管瘤的临床疗效。方法：回顾性系列病例研究。选择2010年2月至2018年8月于北京同仁眼科中心临床和影像学确诊为孤立性脉络膜血管瘤患者43例（43眼），所有患者都存在渗出性视网膜脱离，经国产敷贴器进行巩膜外敷贴放射治疗。彩色超声多普勒测量瘤体大小（最大基底直径和最大高度），间接眼底镜、光学相干断层扫描观察视网膜下液情况，比较术前和末次随访时视力、眼压、瘤体大小及视网膜下液的变化，并观察有无并发症的发生。治疗前后瘤体最大基底径、瘤体高度比较采用配对t检验进行分析，治疗前后视力、眼压比较采用 Wilcoxon秩和检验进行分析。结果：43例患者末次随访LogMAR视力（2.03±1.45）与术前（2.14±1.36）比较，差异有统计学意义（Z=-2.348，P=0.019）。末次随访眼压为（13.6±6.0）mmHg（1 mmHg= 0.133 kPa）与术前的（12.5±4.2）mmHg比较，差异无统计学意义（Z=-1.419，P=0.3）。末次随访瘤体最大基底直径为（10.3±2.5）mm，较术前的（12.3±3.2）mm缩小，差异有统计学意义（t=8.862，P<0.001）；末次随访瘤体高度为（2.6±1.3）mm，较术前的（4.8±1.4）mm降低，差异有统计学意义（t=10.387，P<0.001）。所有患者在末次随访时视网膜下液完全吸收，未观察到放射性视神经病变、视网膜病变、黄斑病变或放射性白内障的发生。结论：国产敷贴器巩膜外敷贴可以使孤立性脉络膜血管瘤的瘤体缩小，视网膜下液吸收，从而避免眼球摘除，并保留视功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：脉络膜血管瘤, 放射治疗, 敷贴器, 放射性碘¹²⁵

Abstract：

Objective: To evaluate the clinical efficacy of a domestic radioactive applicator for the treatment of circumscribed choroidal hemagioma. Methods: This was a retrospective consecutive observational study. Forty-three patients were diagnosed clinically and radiologically with circumscribed choroidal hemagiomain Beijing Tongren Hospital from February 2010 to August 2018. All patients had exudative retinal detachment and were treated by a domestic radioactive applicator. The size of the tumor (maximum base diameter, maximum height) was recorded by color doppler ultrasound imaging (CDI). Changes insubretinal fluid were observed by indirect ophthalmoscopy and optical coherence tomography (OCT). The changes invisual acuity, intraocular pressure, tumor size and subretinal fluid were compared before and after surgery and the occurrence rates of complications were noted. Data were compared by a paired t-test and Wilcoxon rank sum test. Results: There was a statistically significant difference in visual acuity between the most recent follow-up (2.03±1.45) and pre-operation (2.14±1.36) (Z=-2.348, P=0.019), and no significant difference in intraocular pressure between the most recent follow-up (13.6±6.0 mmHg) and pre-operation (12.5±4.2 mmHg) (Z=-1.419, P=0.3). Tumor size had regressed compared to pre-operative measurements inmaximum basal diameter: The most recent follow-up was 10.3±2.5 mm, pre-operation was 12.3±3.2 mm (t=8.862, P<0.001); maximum height: the most recent follow-up was 2.6±1.3 mm, pre-operation was 4.8±1.4 mm (t=10.387, P<0.001). Subretinal fluid was not observed in any patients. Furthermore, damages to the optic nerve, retina and macula or radiational cataract were not observed. Conclusion: A domestic radioactive applicator can be used to treat circumscribed choroidal hemagioma, which can cause the tumor to regress, lead to absolute absorption of the subretinal fluid, avoid enucleation and protect visual function.

Key words：

choroidal hemangioma radiotherapy applicator radioactive Iodine¹²⁵

收稿日期: 2018-10-08

基金资助:

北京市医院管理局“登峰”人才培养计划（DFL20150201）；北京市自然科学基金（7151003）；

北京市卫生系统高层次卫生技术人才培养计划（2014-2-003）；首都卫生发展科研专项项目（2016-1- 2051）

通讯作者: 魏文斌（ORCID：0000-0002-0086-6379），Email：weiwenbintr@163.com

引用本文:

刘月明延艳妮李洋魏文斌. 国产敷贴器治疗孤立性脉络膜血管瘤的临床效果[J]. 中华眼视光学与视觉科学杂志, 2019, 21(8): 576-580. Yueming Liu, Yanni Yan, Yang Li, Wenbin Wei. The Safety and Efficacy of a Domestic Radioactive Applicator for the Treatment of Circumscribed Choroidal Hemangioma. Chinese Journal of Optometry Ophthalmology and Visual science, 2019, 21(8): 576-580. DOI: 10.3760/cma.j.issn.1674-845X.2019.08.003

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.issn.1674-845X.2019.08.003 或 https://www.cjoovs.com/CN/Y2019/V21/I8/576

[1]	Shields CL, Honavar SG, Shields JA, et al. Circumscribed choroidal hemangioma: Clinical manifestations and factors predictive of visual outcome in 200 consecutive cases.
	Ophthalmology, 2001, 108(12): 2237-2248.
[2]	Mashayekhi A, Shields CL. Circumscribed choroidal hemangioma. Curr Opin Ophthalmol, 2003, 14(3): 142-149.
[3]	蔡善钰, 卢凤才, 王光璐, 等. I125巩膜敷贴器的研制与临床观察. 中国原子能科学研究院年报, 2004, 27(1): 141-142.
[4]	陈子才, 吴猛, 刘晓琳. 碘125眼巩膜敷贴器的计量学特性的研究. 核技术, 2001, 24(5): 393-397.
[5]	Aizman A, Finger PT, Shabto U, et al. Palladium 103 (103Pd) plaque radiation therapy for circumscribed choroidal hemangioma with retinal detachment. Arch Ophthalmol, 2004,
12	2(11): 1652-1656. DOI: 10.1001/archopht.122.11.1652.
[6]	Zografos L, Bercher L, Chamot L, et al. Cobalt-60 treatment of choroidal hemangiomas. Am J Ophthalmol, 1996, 121(2): 190- 199.
[7]	Agrawal R, Lavric A, Restori M, et al. Nodular posterior scleritis: Clinico-sonographic characteristics and proposed diagnostic criteria. Retina, 2016, 36(2): 392-401. DOI: 10.1097/
	IAE.0000000000000699.
[8]	Torres VL, Brugnoni N, Kaiser PK, et al. Optical coherence tomography enhanced depth imaging of choroidal tumors. AmJ Ophthalmol, 2011, 151(4): 586-593. DOI: 10.1016/j.ajo.2010.09.028.
[9]	Madreperla SA, Hungerford JL, Plowman PN, et al. Choroidal hemangiomas: Visual and anatomic results of treatment by photocoagulation or radiation therapy. Ophthalmology, 1997, 104(11): 1773-1778.
[10]	Shields JA, Shields CL, Materin MA, et al. Changing concepts in management of circumscribed choroidal hemangioma: The 2003 J. Howard Stokes Lecture, Part 1. Ophthalmic Surg Lasers Imaging, 2004, 35(5): 383-394.
[11]	Gündüz K. Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma. Surv Ophthalmol, 2004, 49(3): 316-327. DOI: 10.1016/j.survophthal.2004.02.009.
[12]	Gill HS, Simpson R. Transpupillary thermotherapy in the management of juxtapapillary and parafoveal circumscribed choroidal hemangioma. Can J Ophthalmol, 2005, 40(6): 729-
73	3. DOI: 10.1139/i05-062.
[13]	Boixadera A, García-Arumí J, Arumí JG, et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma.
	Ophthalmology, 2009, 116(1):100-105.e1. DOI: 10.1016/j. ophtha.2008.08.029.
[14]	Blasi MA, Tiberti AC, Scupola A, et al. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: Five-year outcomes. Ophthalmology, 2010,
11	7(8): 1630-1637. DOI: 10.1016/j.ophtha.2009.12.033.
[15]	Cerman E, Çekiç O. Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol, 2015, 60(6): 557-574. DOI: 10.1016/j.survophthal.2015.05.004.
[16]	Kwon HJ, Kim M, Lee CS, et al. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma. Am J Ophthalmol, 2012, 154(1): 137-145. DOI:
10	1016/j.ajo.2012.01.007.
[17]	Schilling H, Sauerwein W, Lommatzsch A, et al. Longterm results after low dose ocular irradiation for choroidal haemangiomas. Br J Ophthalmol, 1997, 81(4): 267-273. DOI:
10	1136/bjo.81.4.267.
[18]	Levy-Gabriel C, Rouic LL, Plancher C, et al. Long-term results of low-dose proton beam therapy for circumscribed choroidal hemangiomas. Retina, 2009, 29(2): 170-175. DOI: 10.1097/IAE. 0b013e31818bccfb.
[19]	Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: Long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol, 2000, 118(9): 1219-1228.